Thursday, 15 October 2026European Markets

PORCELEYNE FLES And LDC Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - porceleyne fles (porf.as) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
porceleyne fles (porf.as) €12.80 4.3% 1.02%
ldc (loup.pa) €136.00 2.48% 15.32%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. porceleyne fles (porf.as)

4.3% forward dividend yield and 1.02% return on equity

b.v. delftsch aardewerkfabriek "de porceleyne fles anno 1653" produces and sells delft blue decorative pottery and modern pottery products in the netherlands. it is involved in the purchasing, operation, management, and leasing of real estate properties. the company was founded in 1653 and is based in delft, the netherlands.

earnings per share

as for profitability, porceleyne fles has a trailing twelve months eps of €0.15.

pe ratio

porceleyne fles has a trailing twelve months price to earnings ratio of 85.33. meaning, the purchaser of the share is investing €85.33 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.02%.

volume

today's last reported volume for porceleyne fles is 400 which is 497.01% above its average volume of 67.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, porceleyne fles's stock is considered to be overbought (>=80).

more news about porceleyne fles.

2. ldc (loup.pa)

2.48% forward dividend yield and 15.32% return on equity

l.d.c. s.a. produces and sells poultry and processed products in france and internationally. the company also offers ready-cooked dishes, pizzas, pancakes and biscuits, and sandwiches, as well as fresh and frozen products. it offers its products under the le gaulois, maître coq, loué, marie, poule & toque, nature & respect, drosed, goldenfood, and doux brands. the company was founded in 1909 and is based in sablé-sur-sarthe, france.

earnings per share

as for profitability, ldc has a trailing twelve months eps of €16.44.

pe ratio

ldc has a trailing twelve months price to earnings ratio of 8.27. meaning, the purchaser of the share is investing €8.27 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.32%.

volume

today's last reported volume for ldc is 292 which is 76.77% below its average volume of 1257.

yearly top and bottom value

ldc's stock is valued at €136.00 at 22:30 est, way below its 52-week high of €159.00 and way above its 52-week low of €112.50.

revenue growth

year-on-year quarterly revenue growth grew by 2.1%, now sitting on 6.2b for the twelve trailing months.

moving average

ldc's worth is under its 50-day moving average of €146.05 and under its 200-day moving average of €136.57.

more news about ldc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com